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Recent investigations have established that tumour cells treated in vitro by photodynamic therapy (PDT) can be used for generating
potent vaccines against cancers of the same origin. In the present study, cancer vaccines were prepared by treating mouse SCCVII
squamous cell carcinoma cells with photosensitiser chlorin e6-based PDT and used against poorly immunogenic SCCVII tumours
growing in syngeneic immunocompetent mice. The vaccine potency increased when cells were post-incubated in culture after PDT
treatment for 16h before they were injected into tumour-bearing mice. Interfering with surface expression of phosphatidylserine
(annexin V treatment) and apoptosis (caspase inhibitor treatment) demonstrated that this post-incubation effect is affiliated with the
expression of changes associated with vaccine cell death. The cured mice acquired resistance to re-challenge with the same tumour,
while the engagement of cytotoxic T lymphocytes was demonstrated by detection of high numbers of degranulating CD8
þ cells in
vaccinated tumours. The vaccines prepared from ex vivo PDT-treated SCCVII tumour tissue were also highly effective, implying that
surgically removed tumour tissue can be directly used for PDT vaccines. This opens attractive prospects for employing PDT vaccines
tailored for individual patients targeting specific antigens of the patient’s tumour.
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Although photodynamic therapy (PDT) is established for clinical
treatment of neoplastic and other lesions (Dougherty et al, 1998;
Brown et al, 2004; Huang, 2005), this modality is under continued
investigation for improved efficacy and expanded use. The
destruction of targeted lesions by PDT results from localised
production of reactive oxygen species mediated by drugs
(photosensitisers) capable of capturing the energy of light and
transferring it to molecular oxygen (Henderson and Dougherty,
1992; Dougherty et al, 1998). Unlike immunologically silent
genotoxic damage produced by radiotherapy and chemotherapy,
photooxidative cytotoxic lesions generated by PDT are extra-
nuclear and result in a rapid cell death that alerts host’s immune
surveillance elements (Castano et al, 2006; Gollnick et al, 2006;
Korbelik, 2006). Hence, tumour PDT induces a strong host
response mediated by innate immune system and characterised
by overt inflammatory and acute phase responses that culminates
in the acquirement of adaptive immunity recognising the treated
tumour as its target (Korbelik, 2006).
A particularly interesting exploitation of the immune-activating
capacity of PDT is the development of PDT-generated vaccines.
The preparation designed by Gollnick et al (2002), made of the
lysates of mouse tumour cells treated in vitro by PDT, was shown
to effectively protect against challenge of mice with the same
tumour cells. The authors showed that the action of this
prophylactic vaccine is associated with phenotypic and functional
maturation of dendritic cells and the induction of a cytotoxic T-cell
response, and is based on tumour-specific immune response
(ineffective against mismatched tumour types). Therapeutic PDT
vaccine preparations based on whole tumour cells were developed
in our laboratory (Korbelik and Cecic, 2003; Korbelik and Sun,
2006). In this case, vaccination with in vitro expanded and PDT-
treated mouse squamous cell carcinoma SCCVII cells of mice-
bearing established subcutaneous SCCVII tumours produced
growth retardation and cures of these poorly immunogenic
lesions. The therapeutic effect was also shown to be based on the
elicited tumour-specific adaptive immune response (Korbelik and
Sun, 2006). The distinctive advantage in using PDT for the
generation of cancer vaccines is evidenced by the fact that this
cannot be rivalled by comparable treatments with tumour cells
exposed to X-rays, UV, hyperthermia or their freeze-thaw lysates
(Gollnick et al, 2002; Korbelik and Sun, 2006). This advantage, as
well as more favourable perspectives compared to other polyvalent
vaccination strategies like whole cell RNA-mediated transfection
(Heisler et al, 2001), appears to be imparted by a combination of
highly amplified immunogenicity rendered through photooxida-
tive alterations of tumour proteins and delicate balance of
apoptotic and necrotic death induced in vaccine cancer cells (as
will be further circumstantiated in the present work).
Despite increasing numbers of identified tumour-specific
antigens, there are clear advantages of whole-cell/polypeptide
vaccination over targeting specific epitopes. The polyvalent
vaccines, such as autologous whole-cell vaccines represented by
PDT vaccines, secure greater coverage of potential/diverse tumour
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santigens (even if most of them are unknown) and include the
necessary determinants for helper T cells (Copier and Dalgleish,
2006; Emens, 2006). Autologous whole-cell vaccines are optimally
conditioned to express antigens in patient-matched MHC and are
less likely to encounter ‘tumour escape’ by downregulation of
antigen expression (Khong and Restifo, 2002; Emens, 2006).
Clinically significant benefit using such autologous approach has
been established from randomised trials for colorectal and renal
cancer (Uyl-de Groot et al, 2005; Zhou et al, 2005). The possibility
of tailoring individual vaccines matching the antigenic profile of
patient’s tumour (Hoos et al, 2004; Lewis, 2004) is illustrated in the
present report that also describes further advances in improving
the potency of PDT vaccines and gives new insights on the
underlying mechanisms.
MATERIALS AND METHODS
Tumour model
Mouse squamous cell carcinoma SCCVII, recognised as an
excellent model for poorly immunogenic head and neck cancer
of spontaneous origin (Khurana et al, 2001), was maintained in
vivo by serial transplantation into syngeneic C3H/HeN mice.
Experimental tumours were initiated by injecting subcutaneously
1 million cells in the lower dorsal region of 7–9 weeks old female
mice. The cultures of SCCVII cells in vitro were grown in Alpha
Minimal Essential Medium (Sigma Chemical Co., St Louis, MO,
USA) supplemented with 10% fetal bovine serum (HyClone
Laboratories Inc., Logan, UT, USA). The vaccination was carried
out as a single peritumoral injection (unless stated differently), and
was performed at 6 days post-tumour implant when these lesions
reached 5mm in largest diameter. After vaccination, tumour sizes
were monitored by measuring the lesion’s three orthogonal
diameters with a caliper. The follow-up period after vaccination
lasted until the tumours in control groups became too large
(412mm largest diameter) for keeping the mice due to ethical
considerations. In cases of vaccine-induced complete tumour
regression, the mice were kept under observation for up to 90 days
and those remaining tumour-free at that time were declared cured.
Each treatment group consisted of six mice. The protocols used
with mice were approved by the Animal Care Committee of the
University of British Columbia.
Vaccine generation
In initial experiments, vaccine generation procedure described in a
previous report (Korbelik and Sun, 2006) was followed with the
exception of using photosensitiser chlorin e6 (Ce6, Frontier
Scientific Inc., Logan, UT, USA); this is referred to as ‘standard
vaccine protocol’. Briefly, required numbers of SCCVII cells were
incubated with ce6 (0.5 or 2.5mgml
 1) in serum-free medium for
30min at 371C, washed and exposed to 1Jcm
 2 (15mWcm
 2)o f
665±10nm light, then treated with X-rays (60Gy), and immedi-
ately thereafter injected peritumorally (2 10
7cells per mouse,
0.2ml volume). The light source used was an FB-QTH-3 high
throughput illuminator (Sciencetech Inc., London, Ontario,
Canada) equipped with a 150W QTH lamp and suitable
interference filter. The X-ray source was Philips RT 250 (250kV,
0.5mm Cu, dose rate 3.26Gymin
 1). Control groups included
tumour-bearing mice injected with the same number of SCCVII
cells that received only X-ray treatment (no PDT).
In the course of this study a new protocol was developed
referred to as ‘post-incubation vaccine protocol’. It differs from the
standard vaccine protocol only in including a 16-h (overnight)
incubation of SCCVII cells at 371C after they were treated with
PDT light; the cells were kept in a specially enriched serum- and
protein-free medium (S8284, Sigma) distributed at 4 10
7 cells per
175cm
2 T-flask with 20ml medium. The cells were then
concentrated for X-ray treatment and injection into mice. The
medium in which the cells were ‘post-incubated’ was in some cases
also collected, then concentrated using molecular filters (Centricon
Plus-80, 30,00 MWCO, by Millipore Corporation, Bedford, MA,
USA), and included together with the vaccine cells into the 0.2-ml
volume injected into mice.
To investigate the role of apoptotic cell death in PDT vaccine
cells, apoptosis blocking agent caspase-3 inhibitor benzyloxycar-
bonyl-Asp(OMe)-Glu(Ome)-Val-Asp(OMe)-fluoromethyl ketone
(Z-DEVD, purchased from Enzyme Systems Products Inc.,
Livermore, CA, USA) was added to the medium at the concentra-
tion of 33.4mgml
 1 (50mM) at the onset of 16-h post-incubation of
PDT-treated SCCVII cells. Alternatively, the cells were post-
incubated without Z-DEVD but were exposed immediately
thereafter to annexin V (BioVision Research Products, Mountain
View, CA, USA) at the concentration of 0.2mgml
 1 in annexin V
binding buffer (PharMingen BD Biosciences, Mississauga, Ontario,
Canada) for 30min at room temperature. The cells were then
collected, concentrated for X-ray treatment and injected as PDT
vaccine.
For preparing the PDT vaccine from tumour brei, tissue of
growing untreated tumours was finely minced using a pair of
scalpels and frozen until use in liquid nitrogen. Freshly thawed
brei was incubated ex vivo with ce6 (0.5mgml
 1) and further
processed according to the post-incubation vaccine protocol. The
vaccine injection volume (200ml) contained 170ml of wet brei plus
30ml of phosphate-buffered saline (the highest brei concentration
that can pass through the needle).
Flow cytometry
The procedure used was recently described in detail (Korbelik and
Cooper, 2007). Briefly, tumours were excised at 3 days after
vaccination, weighed, enzymatically disaggregated, and the ob-
tained single cell suspensions counted and subjected to surface
staining with antibodies for three-colour flow cytometry. The
antibodies included FITC-conjugated rat anti-mouse CD107a and
PE-conjugated rat anti-mouse CD8 (both from Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), and biotin-labelled rat
anti-mouse CD11b (Mac-1, eBioscience Inc., San Diego, CA, USA).
The latter antibody was detected by streptavidin-conjugated
Cy-Chrome (PharMingen BD Biosciences). The isotype control
for anti-CD107a was rat anti-mouse IgG2a (eBioscience). The
samples were analysed with a Coulter Epics Elite ESP (Coulter
Electronics, Hialeah, FL, USA) including 20000 cells for each test.
Degranulating cytotoxic T lymphocytes were identified as
CD8
þCD107a
þ cells from populations gated negative for myeloid
marker Mac-1.
Additional flow cytometry analysis was carried out for
determining the percentage of apoptotic and necrotic cells that
appear following the post-incubation protocol for PDT vaccine
generation. For this purpose the cells were stained with FITC-
conjugated annexin V followed by PE-conjugated rabbit mono-
clonal antibody against active caspase-3 diluted in Perm/Wash
buffer (all from PharMingen). Apoptotic cells were identified as
positively stained with both antibodies, while necrotic cells were
positively stained only with annexin V.
Statistical analysis
Tumour growth-inhibition results and mouse survival results
were statistically evaluated using log-rank test. The differences
between means of the data from remaining results were analysed
with Mann–Whitney test. Significance level of 5% was set
as a threshold for determining if the groups were statistically
different.
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sRESULTS
The effectiveness of PDT vaccines prepared by employing
photosensitiser ce6 (not tested before for this application) against
subcutaneous SCCVII tumours growing in C3H/HeN mice is
shown in Figure 1. The vaccines were prepared by exposing in
vitro expanded SCCVII cells to either 0.5 or 2.5mgml
 1 ce6 for
30min in serum-free medium followed by treatment with 1Jcm
 2
of 665±10nm light. The PDT dose with the lower ce6 concentra-
tion kills around 2
3 of cells, while treatment involving the higher ce6
concentration is supralethal (data not shown). Immediately
thereafter, the cells were concentrated, treated with a lethal dose
of X-rays and delivered by perilesional injection (2 10
7 per
mouse) to mice-bearing established SCCVII tumours. Except
for the photosensitiser, this procedure followed the protocol
optimised in our previous studies (Korbelik and Sun, 2006). Also
included in this experiment were tumour-bearing mice serving as
vaccine-untreated controls (received only the perilesional injection
of the same volume of saline) and X-ray only controls (received the
perilesional injection of the same number of cells that were treated
only with X-rays). The measurement of tumour sizes after
vaccination revealed that the tumours in both PDT vaccine groups
remained on average smaller than the control tumours, while there
was no obvious difference in sizes of tumours in the group
receiving X-ray only treated cells compared to the control group
(Figure 1A). Statistically significant inhibition of tumour growth
by both PDT vaccines was evident at 4 days post-vaccination, but
the statistical significance could not be reached at the later time
points due to large values of s.d. with the PDT vaccine groups.
These s.d. were large because the PDT vaccines had a strong
impact on some and limited effect on other tumours within the
same treatment group. In such situation, instead of averaging the
size for the whole treatment group it is more informative to
express the result by listing the percentage of tumours that were
significantly growth-inhibited. The results of such analysis, with
tumours smaller than the means minus two-fold s.d. of the control
group qualifying as growth-inhibited, are depicted in Figure 1B.
With both PDT vaccine groups there was a significant therapeutic
effect (Po0.05, statistically evaluated by log-rank test). This was
manifested as an initial growth-inhibitory effect including most or
all tumours and persisting in the one-third of tumours with the
PDT vaccine group based on the lower ce6 dose (0.5mgml
 1) that
appeared more effective than the PDT vaccine using the higher ce6
dose (although statistically the difference was not resolved). In this
experiment, the tumours that qualified as growth-inhibited at 9
days post-vaccination become impalpable and showed no signs of
recurrence up to 90 days post-vaccination which categorises them
as cured. On day 100 post-vaccination, these cured mice were re-
challenged by an inoculum of 1 10
6 SCCVII cells. Subsequent
monitoring showed no tumour growth, which demonstrates that
the mice acquired resistance against the vaccinated tumour.
The ce6 dose of 0.5mgml
 1 was chosen for PDT vaccines in the
remaining experiments of this study. Examined next was the
possibility that the effectiveness of PDT vaccine can be augmented
by keeping the vaccine cells after PDT treatment under culture
conditions at 371C to allow the progression of induced molecular/
biological events that may prove relevant for the vaccine’s action.
Hence, tumour-bearing mice received in the next experiment
either the standard PDT vaccine (cells used immediately after PDT
treatment) or PDT vaccine consisting of cells incubated after
PDT treatment for 16h at growth conditions before harvested
for injection (post-incubation vaccine protocol). The response
(depicted as survival, based on the percentage of mice whose
tumours remained smaller than 100mm
3) is shown in Figure 2. It
can be seen that both vaccination protocols significantly prolonged
the survival of tumour-bearing mice, but the therapeutic benefit
was significantly better after the post-incubation vaccine protocol
and produced tumour cures with one-third of treated mice. Hence,
this more effective vaccine protocol was adopted for the remaining
experiments in this study.
In the next experiment, one group of tumour-bearing mice
received the vaccine that contained not only PDT-treated cells
collected after the post-incubation protocol but also the concen-
trated supernatant (medium) collected from the same cultures. At
5, 7 and 9 days post-vaccination the tumours in this group were
significantly smaller than the tumours in unvaccinated control
group but their size was not significantly different than the size of
tumours in the group that received the PDT-treated and post-
incubated cells without the supernatant (Figure 3). On the basis of
these results, it appears that adding the supernatant concentrate to
the cells affords no additional benefits. A detectable effect was also
observed with the supernatant concentrate used alone, but it was
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Figure 1 The effect of photodynamic therapy (PDT)-generated vaccine
prepared using photosensitiser ce6 on growth of established SCCVII
tumours. The vaccine was prepared by standard vaccine protocol (see
Materials and Methods section) involving the incubation of SCCVII cells
with ce6 (0.5 or 2.5mgml
 1) for 30min, then illumination (1Jcm
 2), and
exposure to X-rays (60Gy) followed immediately by their injection in
SCCVII tumour-bearing mice (2 10
7cells per mouse, peritumorally). The
therapy response was monitored by tumour size measurement and is
presented as (A) means for tumour volume values plus s.d., and (B)
percentage of growth-inhibited tumours (smaller than the means minus
two-fold s.d. of unvaccinated control group). The controls are showing
growth of vaccine untreated and X-ray only vaccine treated tumours. Each
treatment group consisted of six mice. *Indicates statistical significance
(Po0.05) for the difference in tumour growth compared to untreated
controls.
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sinferior to that obtained with cell-based vaccines (data not shown).
Aliquots of these cells taken after the post-incubation PDT vaccine
protocol were analysed by flow cytometry, which showed that
40–50% of them were apoptotic (positively stained with antibody
against active caspase-3 and annexin V) and around 10% were
necrotic (stained with annexin V but not positive with anti-active
caspase 3).
Exposure of PDT vaccine cells after the 16-h post-incubation to
annexin V (known to bind phosphatidylserine) dramatically
affected the efficacy of the vaccine. While PDT vaccine not
involving annexin V exposure strongly inhibited tumour growth
(statistically significant effect, Po0.05), this effect was almost
completely abolished in mice receiving annexin V modified
vaccine (Figure 4). An assumption that phosphatidylserine as a
cell death marker is relevant in this situation was supported by the
results of experiments in which Z-DEVD, inhibitor of apoptosis,
was included in the cell medium during the 16-h post-incubation
of PDT vaccine cells. Compared to very effective tumour growth
inhibition by PDT vaccine not involving Z-DEVD treatment
(statistically significant reduction in tumour sizes from day 6
onwards) eventually manifested as tumour cures in two-thirds of
treated mice, the effect on tumour growth of Z-DEVD modified
PDT vaccine was greatly diminished (statistically greater tumour
sizes for days 11–18 compared to PDT vaccine only group) and
produced no tumour cures (Figure 5).
The results of previous investigations of PDT vaccines suggest
that their effect is based on the action of tumour-specific cytotoxic
T lymphocytes (Gollnick et al, 2002; Korbelik and Sun, 2006). To
obtain direct evidence for this, tumours were collected at 3 days
after vaccination (PDT vaccine generated by the post-incubation
protocol followed by standard X-ray dose) and disaggregated for
obtaining single cell suspensions for flow cytometry analysis.
For detecting degranulating cytotoxic T cells (which happens only
when these immune effectors encounter their specific targets)
staining was performed with anti-mouse CD107a antibody.
Lysosome-associated membrane protein-1 (designated CD107a)
is expressed on the surface of these cells only after exocytosis of
their granzyme and perforin-rich granules that happens while
engaging in the attack of specific targets in an antigen-specific
manner (Betts et al, 2003; Burkett et al, 2005). The cells of interest
were identified as positively stained for CD107a and CD8 antigens
and negatively stained for myeloid marker Mac-1. Separately
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Figure 3 Testing of photodynamic therapy (PDT) vaccine cell super-
natant. The PDT vaccine was prepared using the post-incubation protocol
described for Figure 2. In addition to vaccine cells, the vaccine injection in
one group of mice included concentrated post-incubation medium
supernatants. The results are presented as histograms depicting means
for tumour volume plus s.d. Each treatment group consisted of six mice.
*Indicates statistical significance (Po0.05) for the difference in tumour size
compared to the untreated controls at the same time interval.
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Figure 2 Comparison of the effects of photodynamic therapy (PDT)
vaccines prepared by standard and post-incubation protocols. The
preparation of PDT vaccine was based on the treatment of SCCVII cells
with ce6 (0.5mgml
 1) as described for Figure 1, except that 16-h post PDT
incubation was or was not also included (see Materials and Methods
section). The response of SCCVII tumours after peritumoral injection of
2 10
7cells per mouse is presented as survival of mice (terminating when
tumours reached 100mm
3). Each treatment group consisted of six mice.
*Indicates statistical significance (Po0.05) for the difference in survival
compared to untreated controls; **Indicates statistical significance
(Po0.05) for the difference in survival compared to the vaccine with no
post-incubation treatment group.
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Figure 4 The effect of exposing photodynamic therapy (PDT) vaccine
cells to annexin V. Mice-bearing SCCVII tumours received peritumoral
injection of PDT vaccine consisting of SCCVII cells treated by the post-
incubation protocol described for Figure 2, but including in one group also a
30-min exposure of cells to annexin V (0.2mgml
 1, see Materials and
Methods section). The therapy response was monitored by tumour size
measurement and is presented as percentage of growth-inhibited tumours
(same as Figure 1B). Each treatment group consisted of six mice. *Indicates
statistical significance (Po0.05) for the difference in tumour growth
compared to untreated controls; **Indicates statistical significance
(Po0.05) for the difference in tumour growth compared to the annexin
V-modified vaccine treatment group.
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sanalysed were samples from PDT vaccine good early responders
(tumours regressed) and poor early responders (tumours con-
tinued growing). Compared to control unvaccinated tumours,
‘good’ responders contained almost 10-fold higher number of
degranulating CD8 cells at the lesion site, while the number of
these cells in ‘poor’ responders was significantly lower (although
still significantly elevated compared to the control tumours)
(Figure 6). An increase in average number of CD107a
þCD8
þ cells
was also registered in tumours that received control vaccination
(cells treated with X-rays only), but the difference compared to the
unvaccinated controls was not statistically significant.
To test the relevance of the distance of vaccination site from the
targeted tumour, the effects of PDT vaccine delivered locally
(peritumoral injection, lower sacral region) and at a distant site
(subcutaneous injection at dorsal neck site) were compared in the
same experiment. The results, showing the percentage of growth-
inhibited tumours during the post-vaccination follow-up, are
depicted in Figure 7. It is evident that both vaccine treatments
resulted in a pronounced retardation of tumour growth. A strong
growth inhibition was evident already at 3 days after injection and
expressed prominently again after temporal diminution at 5- and
7-day time points. The latter apparent transient alleviation in the
vaccine effect coincides with the switch to more rapid growth
kinetics of control tumours (boosted by blood vessel build-up) that
can be delayed in individual cases; the impact of such growth
pattern with some untreated tumours was not always evident but is
also detectable in Figure 4. Although statistical difference
compared to the unvaccinated control group was attained by both
tumour-localised and distal vaccine treatments, the therapeutic
effect of locally injected vaccine was significantly better than the
distal.
To examine whether tumour tissue can be used directly for PDT
vaccine, brei (minced tissue) of SCCVII tumours (freshly thawed
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Figure 6 Detection of degranulating cytotoxic T lymphocytes in
tumours treated by photodynamic therapy (PDT) vaccine. Mice-bearing
SCCVII tumours received peritumoral injection of PDT vaccine (SCCVII
cells treated by the post-incubation protocol described for Figure 2). The
tumours were excised 3 days later and disaggregated into single cell
suspensions that were stained with antibodies against mouse CD8, CD11b
and CD107a antigens, and analysed by flow cytometry. Degranulating
cytotoxic T lymphocytes were identified as CD8
þCD107a
þ cells in
populations gated negative for staining with myeloid marker CD11b.
Samples from tumours that regressed by the time of excision (good early
responders) and those from tumours that continued growing (poor early
responders) were analysed separately. Also included were samples from
control sham-vaccinated tumours (saline injected) and from tumours
injected with SCCVII cells treated only with X-rays. The experimental
groups consisted of four or five mice. Bars are s.d. *Indicates statistical
significance (Po0.05) for the difference in the number of CD8
þCD107a
þ
cells compared to the untreated control group; **Indicates statistical
significance (Po0.05) for the difference in the number of CD8
þCD107a
þ
cells compared to the poor early responders group;
#Indicates statistical
significance (Po0.05) for the difference in the number of CD8
þCD107a
þ
cells compared to the control X-ray vaccine group.
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Figure 7 Comparison of the effects of locally (peritumorally) or distally
administered photodynamic therapy (PDT) vaccines. Mice-bearing SCCVII
tumours received PDT vaccine (prepared by the post-incubation protocol
described for Figure 2) injected either peritumorally or at a distal location
(subcutaneously at dorsal neck site). Tumour responses are presented as
percentage of growth-inhibited tumours (same as in Figure 1B). Each
treatment group consisted of six mice. *Indicates statistical significance
(Po0.05) for the difference in tumour growth compared to the untreated
controls group; **Indicates statistical significance for the difference in
tumour growth compared to the distal vaccine treatment group.
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Figure 5 The effect of apoptosis inhibition in photodynamic therapy
(PDT) vaccine cells. Mice-bearing SCCVII tumours received peritumoral
injection of PDT vaccine consisting of SCCVII cells treated by the post-
incubation protocol described for Figure 2, except that Z-DEVD
(33.4mgml
 1) was present in the post-incubation medium for one group.
The therapy response was monitored by tumour size measurement and is
presented as the means for tumour volume values plus s.d. Each treatment
group consisted of six mice. *Indicates statistical significance (Po0.05) for
the difference in tumour size compared to the untreated controls at the
same time interval;
#Indicates statistical significance (Po0.05) for the
difference in tumour size compared to the vaccine without Z-DEVD
treatment group at the same time interval. F¼66.7% were tumour free at
90 days post-vaccination.
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exposed ex vivo to ce6-based PDT followed by overnight (16-h)
post-incubation. The samples were then prepared for vaccination
by insuring that each injection contains 170ml of wet brei; this was
treated with X-rays (60Gy) and injected peritumorally. The results
show that the brei-based PDT vaccine was very effective in
inhibiting tumour growth and exhibited potency close to that of
cell-based PDT vaccine tested in the same experiment (Figure 8).
DISCUSSION
It has recently been established that tumour cells treated in vitro
by PDT can be used for generating potent cancer vaccines
(Gollnick et al, 2002; Korbelik and Sun, 2006). Injection of such
whole-cell PDT vaccine into mice-bearing tumours of the same
origin as used for the vaccine generation was shown to produce
significant antitumour effect even with models of poorly
immunogenic carcinoma (Korbelik and Sun, 2006). The specificity
of action against the tumour of vaccine origin was demonstrated
by the ineffectiveness against mismatched tumours and the data
identify immune rejection mechanisms as responsible for this
effect (Gollnick et al, 2002; Korbelik and Sun, 2006). A direct
demonstration of the engagement of cytotoxic T lymphocytes in
the destruction of tumours mediated by PDT vaccine is provided
in the present report. High numbers of degranulating CD8
þ cells
were found in lesions regressing after PDT vaccine treatment and
much lower numbers in the tumours within the same treatment
group that exhibited a poor early responsive (progressing after
vaccination). Elevated numbers of degranulating CD8
þ cells were
also found in tumours treated by a regular (direct) PDT treatment
(Korbelik and Cooper, 2007).
Although PDT vaccine elicited antitumour immune response is
of systemic nature (and cured mice resist tumour re-challenge),
the proximity of vaccination site to the treated lesion is relevant
for the therapy outcome. While PDT vaccines injected at a distal
site were still effective, their impact was inferior to perilesional
treatment. This is probably due to the fact that antigen
presentation to T cells takes place in the lymph nodes nearest to
the vaccine injection site. In case of peritumoral vaccine injection
T-cell activation will be centered in tumour-draining lymph nodes,
which is a location favourable for T-cell trafficking into the
tumour. Thus with the proximal treatment the vaccine effect could
be expressed more rapidly than with the distal. Such delay in PDT
vaccine-mediated immune activity may prove less important in
tumours with slow growth rate.
In our previous studies, we have identified several key
parameters for optimal action of PDT vaccine such as the number
of PDT-treated tumour cells to be used per vaccination and the
concentration for photosensitisers that were employed (Photofrin,
BPD) (Korbelik and Sun, 2006). In the present study, ce6 was
validated as an effective photosensitiser for generating PDT
vaccines and this reveals that various types of photosensitising
drugs can be exploited for such role. There are several advantages
with using ce6. This established and clinically attested photo-
sensitiser (Spikes, 1990; Sheleg et al, 2004) is a simple compound
that is water soluble and quickly penetrates into cells, and only a
brief incubation (30min) is sufficient for producing adequate PDT
effects. Another advantage of ce6 is its low cost and commercial
availability. To stimulate clinically acceptable safety restrictions
for the exclusion of the risk from secondary tumour generation,
the treatment with a lethal X-ray dose was routinely included as
the last step of our protocols for PDT vaccine generation.
This study demonstrates that the potency of PDT vaccine is
increased when vaccine cells remain in culture after PDT treatment
for an additional time interval (post-incubation protocol) to allow
the expression of PDT-induced molecular/biological changes in
these cells. Such changes of possible relevance include the
progression of apoptotic or necrotic death process associated with
the appearance of death signal molecules on the cell surface (Savill
and Fadok, 2000; Patel et al, 2006; Vandivier et al, 2006), and the
expression of genes in PDT-treated cells whose products are
important immune response mediators; a known example are
heat-shock proteins (Gomer et al, 1996; Korbelik et al, 2005),
which appear to have a key role in the action of PDT vaccines
(Korbelik and Sun, 2006). The experiments in which PDT vaccine
cells were exposed to annexin V and apoptosis inhibitor Z-DEVD
(Figures 4 and 5) demonstrate that cell death process and its
markers on the cell surface (such as phosphatidylserine) are
critical for effective immune processing of these cells. Cell death
manipulation is a recognised strategy for augmenting the efficacy
of whole-cell cancer vaccines (Copier and Dalgleish, 2006). Our
recent findings suggest that the gene encoding serum amyloid P
component (SAP), pentraxin protein involved in the disposal of
dead cells, is upregulated in the liver and tumour of PDT vaccine
treated mice (J Sun and M Korbelik, unpublished results). The
process of efferocytosis (removal of dead cells) was recently
recognised as a critically important element in the development of
PDT-induced tumour immunity (Korbelik, 2006). Around half of
PDT vaccine cells collected after the post-incubation protocol were
apoptotic and necrosis was evident in about 10% of cells. We have
not found that factors released from cells during the post-
incubation give additional potency to the PDT vaccine (Figure 3).
However, molecules of small molecular weight were lost when
concentrating the culture supernatants.
Tumour responses to PDT vaccine showed some variation in the
intensity in different experiments. However, in our continuing
studies we are now routinely achieving the cures of the two-thirds
of PDT vaccine treated tumours; this appears to result from
insuring that no tumours are larger than 30mm
3 at the time of
vaccination. Obviously, PDT vaccines are more effective in
eradicating smaller tumour mass but this does not mean that they
cannot be employed for therapy of larger lesions. Decreasing the
tumour burden by radiotherapy before PDT vaccine treatment
allows curing mice with relatively large malignant growth. For
instance, the treatment of SCCVII tumours by 20Gy produced no
permanent cures but if this X-ray dose was followed by PDT
vaccine application (also not curative when used alone with these
tumours) it resulted in 50% tumour cures (M Korbelik, B Stott,
J Sun, unpublished results). We are also confident that the potency
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Figure 8 The effect of photodynamic therapy (PDT) vaccine prepared
directly from tumour tissue. Mice-bearing SCCVII tumours received a
peritumoral injection of PDT vaccine prepared either from SCCVII cells or
from SCCVII tumour tissue brei using in both cases the post-incubation
protocol described for Figure 2). Tumour responses are presented as
percentage of growth-inhibited tumours (same as in Figure 1B). Each
treatment group consisted of six mice. *Indicates statistical significance
(Po0.05) for the difference in tumour growth compared to the untreated
controls group.
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sof PDT vaccines can be further increased by adjuvant immuno-
modulatory treatment.
This study also demonstrates that tumour tissue can be directly
used for the production of PDT vaccine without the need for
generating first cultures of single cancer cells. This has very
important clinical implications, since tumour tissue surgically
removed from the patient can be used for preparing without delay
(and with avoiding difficulties/uncertainties in establishing pri-
mary cancer cell culture) the PDT vaccine material directly tailored
for the individual patient which is acting against tumour antigens
existing in that specific tumour.
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